

THIS DOCUMENT SHOULD BE READ AS A WHOLE. YOUR ATTENTION IS DRAWN TO THE LETTER FROM THE DIRECTORS OF CUSTOMVIS PLC CONTAINING THE UNANIMOUS RECOMMENDATION OF THE BOARD THAT YOU VOTE AGAINST THE PROPOSED RESOLUTIONS.

This document is important and requires your immediate attention. If you are in any doubt about the contents of this document or the action you should take, you are recommended to seek your own personal financial advice from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser (who in the United Kingdom is authorised under the Financial Services and Markets Act 2000) or if you are not resident in the United Kingdom, another appropriately authorised independent financial adviser.

If you have sold or otherwise transferred all of your shares in CustomVis plc, please send this document together with the Form of Proxy to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. However, these documents should not be forwarded or transmitted in or into any jurisdiction in which such act would constitute a violation of the relevant laws and restrictions of such jurisdiction. Persons into whose possession this document and any accompanying documents should come, should inform themselves about and observe any such laws and restrictions. If you have sold only part of your holding Shares in CustomVis plc, you should retain these documents and consult the bank, stockbroker or other agent through whom the sales were effected. No offer, invitation or inducement to acquire shares or other securities in the Company is being made by or in connection with this document. Certain statements made in this document are forward looking statements. Such statements are based on current expectations and are subject to a number of risks and uncertainties that could cause actual results and performance to differ materially from any expected further results or performances, express or implied, by the forward looking statements.



CUSTOMVIS PLC

(a company incorporated in England and Wales under the Companies Act 1985 with Registered Number 04609602)

Notice of General Meeting as requisitioned on behalf of Members in accordance with section 303 of the Companies Act 2006 and Unanimous recommendation of your Board to vote AGAINST all of the proposed resolutions

Notice of a General Meeting of the Company to be held at the offices of Hammonds LLP, 7 Devonshire Square, London EC2M 4YH at 10.00 a.m. local time on 6 July 2009 is set out at the end of this document.

A Form of Proxy for use at the meeting is enclosed with this document and should be returned so as to be received by the Company's registrars, Capita Registrars Limited, Proxy Department, The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU, by no later than 10.00 a.m. local time on 4 July 2009. **EVERY SHAREHOLDER'S VOTE IS IMPORTANT – PLEASE COMPLETE AND RETURN YOUR FORM OF PROXY AS SOON AS POSSIBLE.** Completion and posting of the Form of Proxy will not prevent a shareholder from attending and voting in person at the General Meeting.

Copies of this document will be available free of charge from the Company's website, www.customvis.com, and during normal business hours from the date hereof until 6 July 2009 from the Company's registered office.

Whether or not you intend to be present at the General Meeting, please complete and return the enclosed Form of Proxy as soon as possible and in any event so as to arrive by not later than 10.00 a.m. local time on 4 July 2009.

LETTER FROM THE BOARD OF DIRECTORS

CustomVis PLC

Directors:

Simon Carroll (*Non-Executive Chairman*)
Paul Van Saarloos (*Chief Executive*)
Emanuel Rosen (*Non-Executive Director*)

Registered Address:

7 Devonshire Square
Cutlers Gardens
London EC2M 4YH
United Kingdom

11 June 2009

Dear Shareholder,

REQUISITION OF GENERAL MEETING

As announced on 22 May 2009, the Directors of CustomVis received valid requisitions from certain former Directors (“the Requisition Group”) calling for a General Meeting to consider the removal of certain key Board members as directors of the Company and the appointment of three new directors. Accordingly, set out at the end of this document is a Notice of General Meeting to be held at the offices of Hammonds LLP, 7 Devonshire Square, Cutlers Gardens, London EC2M 4YH at 10.00 a.m. on 6 July 2009 and a proxy form is enclosed with this document.

We wish to advise all shareholders that the Board is unanimously resolved to recommend that shareholders vote AGAINST all of the proposed resolutions. We consider the resolutions to be directly against the interests of the Company and its shareholders as a whole.

This letter sets out the proposed resolutions, gives reasons why your Board unanimously believes they are AGAINST the best interests of CustomVis and its shareholders as a whole and sets out what actions you should take to exercise your vote.

The Board’s reaction to the requisition is outlined below:

- The plan outlined by the Requisition Group is similar to the strategy put forward in 2003, when certain members of the Requisition Group were directors of the Company. At this time there was significant expenditure and substantial loss of share value;
- This 2003 strategy took the Company’s flagship product, the PulzarZ1™ laser, to market prior to resolution of all technical issues, resulting in vastly increased costs of rectification under the regulatory programme of the Therapeutic Goods Administration;
- Under the stewardship of Simon Carroll, who was appointed chairman of the Company on 25 November 2008, your Board has undertaken substantial changes to the Company’s business; namely, redefining its terms of trade and introducing new worldwide distribution channels and a new sales and marketing team, reorganising its internal structure and expanding its corporate governance activities;
- The Company has seen a significant reduction in cash burn rates, a significant increase in revenue and is making good progress towards becoming cash flow positive; and
- The Requisition Group are critical of the Board and management, however, in the opinion of the Board, they appear to offer little or no alternative strategy to take the Company to the next stage of its development.

Before deciding how to vote at this General Meeting the Board asks you to take into consideration the turnaround programme instigated over the last 12 months. The Board questions the performance record of the Requisition Group during their period with the Company and their recent activities together with the history of the proposed directors. Finally, the Board questions their motive for filing the requisition at this time. This action has caused a significant distraction for management and the Board from the core focus of growing the business during this major global financial crisis.

The Requisition Group

The Requisition Group, comprising the beneficial interests of Simon Gordon, Mukesh Jain and William Colvin, has requisitioned a meeting of shareholders' to consider resolutions to remove the current Chairman and the CEO and substitute these Directors with three replacement directors, namely, Simon Gordon as Managing Director, Hugh Grant as Finance Director and Christopher Bell, as a Non-Executive Director.

Shareholders should be aware of the following regarding these individuals that supports your Board's decision to reject the resolutions:

Simon Gordon – was enrolled as Managing Director of CustomVis on the recommendation of the previous Nominated Adviser of the Company at the time of the IPO in July 2003. Prior to being asked to join CustomVis, Mr Gordon had no declared Board experience in public companies. During his time as Managing Director with the Company, he lived in Scotland. The placing price of the shares issued at IPO was 91p. During the 16 months after flotation on AIM before Mr Gordon resigned to pursue non-competing business activities, the share price plummeted to 18p (an 80.2% reduction) taking the market capitalisation from £31.6m to £6.25m.

William Colvin – was enrolled as a Non-Executive Director and appointed Chairman of CustomVis also on the recommendation of the previous Nominated Adviser. During his time on the CustomVis Board, Mr Colvin lived in the UK and was employed as the CEO of a company that operated nursing homes.

On 24 April 2006, when Mr Colvin resigned as Chairman and a Director of CustomVis, the share price was 5p (a 94.5% reduction to the IPO placing price) taking the market capitalisation from £31.6m to £3.24m.

Mukesh Jain – joined the Board as an Executive Director and General Manager on 23 November 2003. By 30 June 2008, his annual salary had risen to £160,384. On 6 August 2008, the Board terminated Mr Jain's employment and under the terms of his contract he underwent a six month period of garden leave. During this time, while receiving full salary, Mr Jain served a writ on the Company claiming an additional payment for unapproved sales and other commissions. The Company is defending the claims.

The Company has also filed a counterclaim for damages against Mr Jain based on the allegation that, during his employment, Mr Jain received personal payments to himself which he did not disclose to CustomVis arising from the sale of a CustomVis laser. Mr Jain has until 19 June 2009 to file his defence to the counterclaim.

The share price at the time Mr Jain joined the Board was 64.5p and at the time of resigning from the Board on 3 September 2008, the share price was 1.8p (a 97.7% reduction) and the market capitalisation reduced from £27.1m to £3.04m over the same period (an 88.8% reduction).

Proposed Directors

In addition to Mr Gordon proposing himself as the Managing Director, Mr Hugh Grant and Mr Christopher Bell have been nominated as proposed directors.

Hugh Grant – was enrolled as Finance Director of CustomVis, also on the recommendation of the previous Nominated Adviser at the time of the IPO in July 2003. Prior to joining CustomVis, Mr Grant had no declared Board experience in public companies. During his time as Finance Director, Mr Grant lived in Scotland. Mr Grant was a director of CustomVis for the same period as Mr Gordon and also presided over a period when the share price fell by 80%.

While Finance Director of the Company, Mr Grant was also employed as a partner of Findlay & Company. Between 2003 and 2008, Findlay & Company was engaged to provide consultancy, payroll, general and taxation accounting services to the Company. As noted in the Company's 2008 Annual Report, the 2005 and 2006 tax computations were significantly understated requiring the current Directors to make taxation provisions for £397,594 in the FY2008 Results. Subsequently this provision has been significantly reduced, after the Board successfully requested the tax authorities to accept restated computations.

Christopher Bell – The Board have not received any details about Mr Bell.

Failure to Submit Valid Requisitions

Shareholders may be aware that the Requisition Group maintained that a requisition had been lodged on 24 April 2009. However, the Articles of Association and legislation required the requisition to be made in a clear and specific way. The Requisition Group failed to do this.

Having been advised by e-mail on 11 May 2009 that the original requisition was invalid, it took the Requisition Group until 21 May 2009 to lodge a valid requisition. Throughout this period the Requisition Group orchestrated an aggressive media campaign and wrote unauthorised letters to shareholders, which we are aware has upset certain shareholders, customers, distributors and CustomVis staff, and which paint a very one-sided view of their proposals.

Why the Requisition Group should not be given Board Control

‘Proposals are not in the Company’s and Shareholders’ best interests’

The Requisition Group have outlined a number of outcomes that they believe will be of benefit to the Company and therefore shareholders. Your Board disagrees strongly with these assertions.

New Board for UK Company – In the opinion of the Board, this proposal will not lead to a new board or better governance. Simon Gordon and Hugh Grant were previously on the Board and left 16 months after the IPO with an 80.2% fall in share price and market capitalisation.

Whilst the Company is listed on AIM in the UK, the operations of the Company are currently in Australia. To set up a Board entirely in the UK with the Managing Director and Finance Director living there is a questionable strategy. Close proximity of a Board to the operations of a small-to-medium sized enterprise allows effective corporate governance. Your Board, with one independent Non-Executive Director in the UK and the Chairman and CEO located near the business in Perth, Australia, is effective from corporate governance, management and cost perspectives.

Cut-overheads – or lead to increased costs? – Simon Gordon, Hugh Grant and William Colvin were directors when the monthly Administration Expense was £368,377. They tolerated substantial duplication of management with a fully serviced UK Office and the Australian facility and while together on the Board failed to achieve any sales revenue. The Board is concerned that the proposal appears to re-establish this duplication.

The Requisition Group maintains it has no pre-determined plan to close down any operations or reduce staff numbers in Australia and that it will conduct a detailed review upon election. Given the fact that Mr Gordon has not been involved with the Company for over four years, shareholders should question why he believes he will have a better strategy for the Company.

Reassess Strengths of Key Staff and Resources – or lead to increased workforce? – During their tenure, Simon Gordon, Hugh Grant, William Colvin and Mukesh Jain built the Company’s workforce level to 69 staff. The Board continuously assesses staff requirement, capability and the application of such resources and has kept the key productive staff while “right-sizing” the workforce to 32 people.

Clinical Trials in Europe, Engage Key Opinion Leaders – The Board has achieved a trial to commence at the world renowned Moorfields Eye Hospital. Unlike the trial proposed by the Requisition Group, Moorfields Eye Hospital is not being paid to perform this trial. The Board has also recently established a Medical Advisory Board with Key Opinion Leaders from the industry around the world. In addition, the Company currently has five lasers operating in Europe.

What clear alternative strategy? – The Requisition Group maintains that it has “a clear alternative strategy”, but the letter to shareholders accompanying this letter fails to state what this alternative strategy is. All the Requisitioning Group states is that it intends to perform a review of the Company’s activities and provide a report to shareholders in two to three months. In our view it has NO clear alternative strategy. What happens to the Company in the intervening period? What if the review concludes that the current strategy IS THE BEST strategy?

In the opinion of the Board, the Requisition Group have failed to demonstrate any credible strategy to enhance shareholder value.

Removal of Key Directors

The Requisition Group has requisitioned resolutions to remove two key directors, the Chairman, Simon Carroll and the CEO, Dr Paul van Saarloos. It has chosen to take this action at a time when the Company continues to make progress towards a cash flow positive position through sales with more favourable terms of trade than previously. The flagship product, the Pulzar™Z1 laser has achieved a worldwide installed base of 40 lasers, enabling 103,550 eyes to be treated.

Bringing high technology products to market in a heavily regulated environment and against strong competition is generally difficult. Against this background the Company has experienced a steady increase in the installed base since 2006 and continues to have high levels of interest at world trade shows.

In addition to the Pulzar™Z1 laser the Company is about to launch a highly portable digital ophthalmoscope and is evaluating another medical device to enhance its ophthalmic product range to maximise leverage of its quality systems and its sales and distribution network. The Company has also recently taken on the Australian distributorship of the iTrace, a leading medical device widely used to measure quality of vision and visual function. The Company has had a supply agreement to sell the iTrace with its Pulzar™Z1 laser since 2004. It has also recently submitted an application to the Therapeutic Goods Administration for the treatment of presbyopia. On approval, the Company will also gain CE Mark for this procedure.

'The Requisition Group's proposals could irreparably harm the prospects for CustomVis shareholders'

Your Board

Simon Carroll – joined the Board in May 2008 and was elected Chairman in November 2008. During this period Mr Carroll has overhauled the corporate governance of the Company and injected a strong focus on business development, cash flow and expenditure reductions. The Chairman has considerable experience in both publicly-listed companies and in technology development and commercialisation, including ophthalmology products. Previously he was CEO of a listed ophthalmic company that had involvement in refractive surgery and he has a good understanding of medical product quality systems having launched more than 25 medical device and biotechnology products in his career.

Dr Paul van Saarloos – has been the CEO since the inception of the Company in 2001. Dr van Saarloos is the key inventor of the technology-leading solid-state Pulzar™Z1 laser and continues to oversee all aspects of product development. He is a serial technology entrepreneur, inventing new technology and gaining marketing approval through the regulatory processes. The Board believes his continued involvement with CustomVis is vital to the future of the Company and it is likely that considerable confidence in the Company's abilities will be lost if Dr van Saarloos was to cease to be involved with the Company, leading to loss of distributors, customers and credibility.

Shareholders should note that Dr van Saarloos is employed as CEO/ Managing Director of the Company. Removal of Dr van Saarloos as a director may affect his employment depending on the response of the Board (including any new members of the Board) to the outcome of the resolution to remove him as a director. Although the removal of Dr van Saarloos as a director is not an event of termination under his employment contract, shareholders should be aware that if Dr van Saarloos's employment is terminated by the Company, Dr van Saarloos may be entitled to a termination payment.

Professor Emanuel Rosen – has been a Director of the Company since its listing on 8 July 2003. As an independent Non-Executive Director, Professor Rosen also served as Chairman between 2006 and 2008. Professor Rosen's position on the Board is not the subject of a resolution proposed by the Requisition Group.

All three current directors have many years experience in ophthalmology and are highly respected in the industry.


This Board wishes to advise shareholders that it has the support of Mr Bob Morton of Hawk Investment Holdings Limited, which has a holding of approximately 22.2% in the share capital of the Company.

Achievements

In the last 12 months, the Board has undertaken a series of key actions and driven major achievements for the Company, including:

- Achieved sales for the first six months of the current financial year equal to 76% of the full year revenue for the previous year. The year-to-date number of lasers installed is now 12 compared with 11 for the previous full year of trading. This is in the face of the global financial crisis and significantly altered terms of trade;
- Significantly increased revenues since 2004/5, with 2008 revenue from sales being £1,161,312 and estimated revenue in FY2009 of £1,700,000 (source: Edison Research) which would represent an annualised growth rate of 46.3%;
- Signed five new sales contracts in the past four weeks, one of which is an outright cash sale, which is expected to be installed by the end of the current financial year;
- Submitted an application for regulatory approval for the treatment of presbyopia that, when granted, will increase the revenue generated by the installed base of Pulzar™Z1 lasers through per treatment fees;
- A new CFO and Company Secretary has been appointed and the position of COO has been dispensed with, all resulting in enhanced financial management;
- Reviewed the corporate governance leading to a Charter for the Board and the Finance and Audit Committee. Subsequent changes to the Board with the resignation of an Executive Director (Mr Jain) resulted in the Board having a majority of Non-Executive Directors, all in line with the principles of good corporate governance;
- Establishment of a Medical Advisory Board, chaired by Professor Rosen and consisting of Key Opinion Leaders from UK, Europe, USA and Australia;
- Structured an independent clinical trial programme with the world-renowned Moorfields Eye Hospital in London, which will commence shortly. Moorfields Eye Hospital is not being paid to perform this trial;
- Supported distributors to provide front-line service on the installed base, thereby enabling the Company to maintain a modestly costed service centre as the installed base grows geographically;
- Reduced the average monthly net operating loss (excluding foreign exchange gains) from £362,693 for the year to 30 June 2004 (audited) to £114,185 for the six months to 31 December 2008 (unaudited) (a 68.5% reduction). This figure includes £13,365 per month salary expense for Mr Jain who has not been replaced;
- Recent laser to be sold for cash and the terms of trade for non-cash sales have been restructured to provide higher initial deposits ; and
- New highly portable digital ophthalmoscope in final evaluation before launch. Other ophthalmic devices are under review to leverage our sales and distribution network.

Set out below is a chart which shows the turnover of the Company for the financial years from 2002/3 to 2008/9 inclusive which demonstrates the progress the Company has made over the period:



The source for the market forecast for the financial year 2008/9 is Edison Research.

Action to be taken

Set out at the end of this document is the Notice of General Meeting to be held at the offices of Hammonds LLP, 7 Devonshire Square, Cutlers Gardens, London EC2M 4YH at 10.00 a.m. on 6 July 2009 and a proxy form is enclosed with this document. Whether or not you intend to be present at the General Meeting, you are asked to complete the Proxy Form so it is received by the Company’s Registrar, Capita Registrars Limited, as soon as possible but in any event not later than **10.00 a.m. on 4 July 2009.**

The Directors believe that the Resolutions are AGAINST the best interests of the Company and its Shareholders as a whole.

Accordingly, the Board unanimously recommends that Shareholders **VOTE AGAINST ALL OF THE RESOLUTIONS** as the Directors intend to do in respect of their beneficial holdings amounting to 9,075,630 Ordinary Shares, representing 5.36 per cent. of the issued share capital of the Company.

Please visit our website www.customvis.com in case a response to future actions of the Requisition Group is warranted.

Yours faithfully

Simon Carroll FAICD
Chairman

Professor Emanuel Rosen
Independent Director

Dr Paul van Saarloos
CEO/Managing Director

Independent Director’s recommendation

I believe that it is in the best interests of shareholders that Mr Carroll and Dr van Saarloos should remain as directors of the Company and strongly urge you to vote against all the resolutions at the forthcoming General Meeting of the Company as I intend to do.

Yours faithfully

Professor Emanuel Rosen

NOTICE OF GENERAL MEETING

AT

10.00 A.M. 6 JULY 2009

HELD AT THE OFFICES OF HAMMONDS LLP

7 DEVONSHIRE SQUARE

CUTLERS GARDENS

LONDON EC2M 4YH

YOUR BOARD RECOMMENDS THAT YOU VOTE

AGAINST

ALL RESOLUTIONS

**The business of the General Meeting affects your shareholding
and your vote is important**

CustomVis PLC

NOTICE OF GENERAL MEETING

NOTICE IS HEREBY GIVEN that a general meeting of CustomVis plc (the "Company") will be held at the offices of Hammonds LLP, 7 Devonshire Square, Cutlers Gardens, London EC2M 4YH United Kingdom on 6 July at 10.00 a.m. local time for the purposes of considering and, if thought fit, passing the following resolutions, which will each be proposed as ordinary resolutions.

Ordinary Resolutions

1. THAT in accordance with section 168 of the Companies Act 2006 Mr Paul van Saarloos be removed from office as a director of the Company with immediate effect.
2. THAT in accordance with section 168 of the Companies Act 2006 Mr Simon Carroll be removed from office as a director of the Company with immediate effect.
3. THAT in accordance with section 168 of the Companies Act 2006 any director appointed after the Company's Annual General Meeting held on 2 February 2009 and prior to the date of the requisition be removed from office as a director with immediate effect.
4. THAT in accordance with section 168 of the Companies Act 2006 any director appointed between the date of the requisition and the date of the proposed General Meeting taking place, be removed from office as a director of the Company with immediate effect.
5. THAT Mr Simon Gordon be appointed as a director of the Company with immediate effect.
6. THAT Mr Hugh Grant be appointed as a director of the Company with immediate effect.
7. THAT Mr Christopher Bell be appointed as a non-executive director of the Company with immediate effect.

BY ORDER OF THE BOARD

Stuart Usher
Company Secretary

Registered Office:
7 Devonshire Square
Cutlers Gardens
London EC2M 4YH

Date: 11 June 2009

Explanatory Notes

1. Members are entitled to appoint a proxy to exercise all or any of their rights to attend, speak and vote on their behalf at the meeting. A proxy need not be a shareholder of the Company.
2. A shareholder may appoint more than one proxy in relation to the General Meeting provided that each proxy is appointed to exercise the rights attached to a different share or shares held by that shareholder. To appoint more than one proxy you may photocopy the Form of Proxy. Please indicate the proxy holder's name and the number of shares in relation to which they are authorised to act as proxy on the proxy form. Please also indicate if the proxy instruction is one of multiple instructions being given. All forms should be signed and returned together in the same envelope.
3. To be valid, the form of proxy and the power of attorney or other authority (if any) under which it is signed or a certified copy of such power or authority must be lodged at the offices of the Company's Registrars, Capita Registrars Limited, Proxy Department, The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU by hand, or sent by post, so as to be received not less than 48 hours before the time fixed for the holding of the meeting or any adjournment thereof (as the case may be).
4. In order to facilitate voting by corporate representatives at the meeting, arrangements will be put in place at the meeting so that (i) if a corporate shareholder has appointed the Chairman of the meeting as its corporate representative with instructions to vote on a poll in accordance with the directions of all of the other corporate representatives for that shareholder at the meeting, then on a poll those corporate representatives will give voting directions to the Chairman and the Chairman will vote (or withhold a vote) as corporate representative in accordance with those directions; and (ii) if more than one corporate representative for the same corporate shareholder attends the meeting but the corporate shareholder has not appointed the Chairman of the meeting as its corporate representative, a designated corporate representative will be nominated, from those corporate representatives who attend, who will vote on a poll and the other corporate representatives will give voting directions to that designated corporate representative. Corporate shareholders are referred to the guidance issued by the Institute of Chartered Secretaries and Administrators on proxies and corporate representatives (www.icsa.org.uk) for further details of this procedure. The guidance includes a sample form of appointment letter if the Chairman is being appointed as described in (i) above.
5. The completion and return of a form of proxy will not preclude a member from attending in person at the meeting and voting should he wish to do so.
6. Copies of the Director's service contracts and the register of interests of the Directors are available for inspection at the company's registered office during normal business hours on any weekday (except Saturdays, Sundays and public holidays) and at the place of meeting for 15 minutes prior to and during the General Meeting.
7. In accordance with Regulation 41 of the Uncertificated Securities Regulations 2001, only those members entered on the Company's register of members not later than 10.00 a.m. on 4 July 2009 or if the meeting is adjourned, shareholders entered on the Company's register of members not later than 48 hours before the time fixed for the adjourned meeting shall be entitled to attend and vote at the meeting.

